Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know
Management of lung disease in patients with alpha-1 antitrypsin deficiency (AATD) includes both non-pharmacological and pharmacological approaches. Lifestyle changes with avoidance of environmental pollutants, including tobacco smoke, improving exercise levels and nutritional status, all encompassed...
Saved in:
Main Authors: | Igor Barjaktarevic (Author), Michael Campos (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Human papillomavirus: What we know and what we doing?
by: Gökhan Doğukan Akarsu, et al.
Published: (2023) -
The Private Library What We Do Know, What We Don't Know, What We Ought to Know About Our Books
by: Humphreys, Arthur Lee, 1865-1946 -
Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know
by: Chuan-bin Sun, et al.
Published: (2020) -
What do we have to know about Cystic Lung Diseases?
by: Sánchez Díaz C, et al.
Published: (2017) -
Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
by: Tadic M, et al.
Published: (2020)